In both the United States and other parts of the world, kidney stones are becoming an increasingly regular occurrence. There is a correlation between type 2 diabetes and an increased risk of kidney stones; however, there are a variety of treatment options available for this condition that have the ability to minimize the risk of kidney stones formation.
The use of sodium-glucose contratransporter 2 (SGLT2) inhibitors was found to be connected with a reduced risk of developing kidney stones, according to the findings of researchers at Mass General Brigham. Their results were later reported in the journal JAMA Internal Medicine.
The investigation was carried out by researchers from Massachusetts General Hospital and Brigham and Women’s Hospital working together to undertake the investigation. The research incorporated information obtained from three national databases pertaining to individuals diagnosed with type 2 diabetes who were seen in the course of their regular clinical practice. In their study, the researchers looked at information from 716,406 people who had type 2 diabetes and had started taking either an SGLT2 inhibitor or one of two additional types of diabetes medications known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors.
In comparison to patients who were using GLP1 agonists, those who started taking SGLT2 inhibitors had a thirty percent lower risk of developing kidney stones, and those who started taking DPP4 inhibitors had a twenty-five percent lower risk altogether. The findings were constant regardless of factors such as gender, race or ethnicity, a previous history of chronic renal illness, or obesity.
“Our findings could help inform clinical decision making for patients with diabetes who are at risk of developing kidney stones,” said corresponding author Julie Paik, MD, ScD, MPH, of Brigham and Women’s Hospital’s Divisions of Pharmacoepidemiology and Pharmacoeconomics and Renal (Kidney) Medicine.
For more information: Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes, JAMA Internal Medicine (2024). DOI: 10.1001/jamainternmed.2023.7660
more recommended stories
New therapies developed by Oxford experts offer online support for anxiety and post-traumatic stress disordersUrgent treatment solutions are needed for.
three key pillars to tackle antimicrobial resistance effectively — University of Oxford, Medical Sciences DivisionThe High-Level Meeting on antimicrobial resistance.
Oxford Vaccine Group marks 30 years battling ‘deadly six’ diseases with major art installation — University of Oxford, Medical Sciences DivisionThe installation was commissioned to mark.
Professor Ahmed Awarded Funding To Create World’s First Ovarian Cancer Prevention Vaccine — University of Oxford, Medical Sciences DivisionScientists at the University of Oxford,.
New research network unites Oxford University’s global fight against antimicrobial resistance — University of Oxford, Medical Sciences DivisionAntimicrobial resistance (AMR) threatens the foundation.
Typhoid vaccine trial confirms sustained protection for older children — University of Oxford, Medical Sciences DivisionThe TyVOID study, published in the Lancet, measured the.
Study Publishes New Insights on Goblet Cell Differentiation in Colorectal Cancer — University of Oxford, Medical Sciences DivisionThe research addresses the long-recognized poor.
Four Oxford researchers win prestigious Philip Leverhulme Prizes — University of Oxford, Medical Sciences DivisionOnly 30 prizes are awarded throughout.
Kavli Oxford’s Nick Gatford Wins Image of Distinction Award in Nikon Small World Competition — University of Oxford, Medical Sciences DivisionThe Nikon Small World competition, often.
Ineos Oxford Institute awards over £2m to innovative projects to tackle antimicrobial resistance — University of Oxford, Medical Sciences DivisionThe IOI Synergy Grants scheme is.
Leave a Comment